New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 6, 2014
07:16 EDTCANFCan-Fite BioPharma submits Phase II study protocol with CF102
Can-Fite BioPharma announced that a Phase II study protocol for the treatment of advanced liver cancer with its CF102 drug candidate has been submitted. The company plans to conduct the Phase II study in Israel, Europe and the US and will include 78 subjects with second-line treatment of advanced hepatocellular carcinoma with Child-Pugh Class B cirrhosis. The study will investigate the efficacy and safety of CF102 vs. placebo. The US Food and Drug Administration has granted Orphan Drug designation for CF102, for the treatment of hepatocellular carcinoma. According to Global Industry Analysts, the global liver cancer drug market is expected to exceed $2B by 2015.
News For CANF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
07:07 EDTCANFCan-Fite BioPharma reports favorable data from Phase II/III CF101 study
Can-Fite BioPharma announced favorable data from further analysis of its Phase II/III double-blind, placebo-controlled study designed to test the efficacy of CF101 in patients with moderate-to-severe plaque psoriasis. The study included 326 patients through 17 clinical centers in the U.S., Europe, and Israel with a duration of 32 weeks where the primary endpoint was after 12 weeks. On March 30 Can-Fite announced the study did not meet its primary endpoint of a statistically significant improvement in the Psoriasis Area Severity Index, or PASI, 75 score relative to placebo after 12 weeks of treatment. However, based on further analysis of the efficacy and safety results from the study as described below, Can-Fite intends to continue the development of CF101 for the treatment of psoriasis and has initiated work on the design of the next advanced–stage clinical trial protocol.
April 20, 2015
07:02 EDTCANFCan-Fite BioPharma applies for Orphan Drug Designation in Europe for CF102
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use